A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 647
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DDI
Long Form : drug-drug interaction
No. Year Title Co-occurring Abbreviation
2019 A comparison of potential psychiatric drug interactions from six drug interaction database programs. ---
2019 A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ---
2019 A two-stage deep learning approach for extracting entities and relationships from medical texts. biLSTM, CNN, CRF, NER, RE
2019 Aldehyde oxidase and its role as a drug metabolizing enzyme. AO, XO
2019 An Automated Detection System of Drug-Drug Interactions from Electronic Patient Records Using Big Data Analytics. ADEs
2019 Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. ASV, cART, CD4, DAA, DCV, GT, HCV, HIV, PR, RNA, SOF, SVR24
2019 Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach. AUC, Kp,uu,rat, PBPK
2019 Applying Two Orthogonal Methods to Assess Accuracy of Plasma Protein Binding Measurements for Highly Bound Compounds. fu, PPB
2019 Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. PKs, SHPT
10  2019 Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. ---
11  2019 Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited. P-gp, PKP
12  2019 City-wide electronic health records reveal gender and age biases in administration of known drug-drug interactions. ADR, EHR
13  2019 Comparison of the inhibition potential of parthenolide and micheliolide on various UDP-glucuronosyltransferase isoforms. 4-MU, Ki, MCL, PTL, UGTs
14  2019 Concomitant use of Cotrimoxazole and Atazanavir in HIV-infected patients: A Therapeutic Drug Monitoring and Pharmacovigilance based dual approach. AOR, aROR, ATV, PV, TDM
15  2019 Contraindicated drug-drug interactions associated with oral antimicrobial agents prescribed in the ambulatory care setting in the United States. CI
16  2019 CuDDI: A CUDA-Based Application for Extracting Drug-Drug Interaction Related Substance Terms from PubMed Literature. CUDA
17  2019 Cushing's syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case-control study in the French Pharmacovigilance Database. CS, FPVD, PLWH
18  2019 Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective. ATZ, IVRs, LNG, PK
19  2019 Differential pharmacokinetic drug-drug interaction potential of eletriptan between oral and subcutaneous routes. ---
20  2019 Dioscorea bulbifera L. delays the excretion of doxorubicin and aggravates doxorubicin-induced cardiotoxicity and nephrotoxicity by inhibiting the expression of P-glycoprotein in mice liver and kidney. AST, CK, CK-MB, Cr, DOX, P-gp
21  2019 Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. EPP, fT, IVIVE, OATP
22  2019 Drug Interactions of Chronic Neuropsychiatric Drugs in Neuro-critical Care. PDDI
23  2019 Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. AUC, PBPK
24  2019 Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. AR, BCRP, nmCRPC, OAT, OATP, P-gp
25  2019 Drug-Drug Interaction Predicting by Neural Network Using Integrated Similarity. ---
26  2019 Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned. ---
27  2019 Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. FHT, PK, PrEP, TFV, TGW
28  2019 Drug-drug interactions when treating HIV-related metabolic disorders. HIV
29  2019 Drug-drug interactions you should know! ---
30  2019 Drug-drug Interactions You Should Know! ---
31  2019 Drug-drug interactions you should know! ---
32  2019 Effects of food type on the extent of drug-drug interactions between activated charcoal and phenobarbital in rats. AUC
33  2019 Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study. ---
34  2019 Elucidation of N1-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters. m1A, m1A
35  2019 Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. AEs, nmCRPC
36  2019 Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. pDDIs
37  2019 Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia. HHTg, P-gp, STD
38  2019 Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. AG, OATP1B1, PK
39  2019 Fixed-dose combination antihypertensives and risk of medication errors. FDC, RR
40  2019 From Endogenous Compounds as Biomarkers to Plasma-Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational Pharmacokinetics-Absorption, Distribution, Metabolism, Excretion-Drug-Drug Interaction Science Finally Arrived? ADME, PK
41  2019 Graph Embedding on Biomedical Networks: Methods, Applications, and Evaluations. DDA, PPI
42  2019 Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. ADRs, FPDB
43  2019 Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies. ---
44  2019 Incorporating User Generated Content for Drug Drug Interaction Extraction Based on Full Attention Mechanism. UGC
45  2019 Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples. BBW, RM, TKI
46  2019 KMR: knowledge-oriented medicine representation learning for drug-drug interaction and similarity computation. DDS
47  2019 Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats. RLM
48  2019 Leveraging genetic interactions for adverse drug-drug interaction prediction. ---
49  2019 Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies. AUC, CAN, IS, MET, OCT, PGT
50  2019 Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017. AUC, OATP
51  2019 Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1. AUCR, OATP1B1
52  2019 Mining Directional Drug Interaction Effects on Myopathy Using the FAERS Database. FAERS
53  2019 Natural Language Processing for EHR-Based Computational Phenotyping. ADE, EHRs, NLP
54  2019 Negligible impact of highly patient-specific decision support for potassium-increasing drug-drug interactions - a cluster-randomised controlled trial. CDS
55  2019 No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study. CI, GMR, OATP, PKs
56  2019 Optimising computerised decision support to transform medication safety and reduce prescriber burden: study protocol for a mixed-methods evaluation of drug-drug interaction alerts. EMM
57  2019 Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. KO, Oatp1b2, WT
58  2019 Patient preferences for objective quality metrics during community pharmacy selection: A discrete choice experiment. ---
59  2019 Performance Evaluation of Clinical Decision Support Systems (CDSS): Developing a Business Intelligence (BI) Dashboard. BI, CDSS, EHR
60  2019 Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates. PBPK, PK
61  2019 Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor. AUC, P-gp, PKs
62  2019 Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. ---
63  2019 Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. PBPK
64  2019 Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam. AUC
65  2019 Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface. ARAs, PPIs
66  2019 Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes. DME, PBPK, PK, QSAR
67  2019 Prediction of the Impact ofCytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations. AUCR, PK
68  2019 Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions. mTOR, OATP
69  2019 Pretreatment with broad-spectrum antibiotics alters the pharmacokinetics of major constituents of Shaoyao-Gancao decoction in rats after oral administration. AF, GA, GL, ILA, ILT, LA, LT, PF, SGD
70  2019 Prevalence of cytochrome P450-mediated potential drug-drug interactions in residents of intermediate care facilities for older adults in Japan. ---
71  2019 Prevalence of high-risk drug-drug interactions in paediatric inpatients: a retrospective, single-centre cohort analysis. ADEs, CDSS
72  2019 Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies. PK
73  2019 Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. CIs
74  2019 Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model. CYP3A, ITZ, WG
75  2019 Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins. BCRP, DABE, HEK, MATE, MATE1, P-gp
76  2019 Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase. WHO
77  2019 Similarity-based machine learning support vector machine predictor of drug-drug interactions with improved accuracies. ADE, IPF, SIDER, SVMs
78  2019 Structured override reasons for drug-drug interaction alerts in electronic health records. ---
79  2019 Systematic Development and Verification of A Physiologically-Based Pharmacokinetic Model of Rivaroxaban. AF, DDDIs, OAT, P-gp, PBPK
80  2019 The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women. COC, EE, HD, LNG
81  2019 The Effect of Patient-Specific Drug-Drug Interaction Alerting on the Frequency of Alerts: A Pilot Study. CDS
82  2019 The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study. OST
83  2019 Theoretical consideration of the properties of intestinal flow models on route-dependent drug removal: Segregated Flow (SFM) vs. Traditional (TM). MBI, SFM, TM
84  2019 Unremarkable impact of Oatp inhibition on the liver concentration of fluvastatin, lovastatin and pitavastatin in wild-type and Oatp1a/1b knockout mouse. KO
85  2019 Update on Therapeutic Protein-Drug Interaction: Information in Labeling. PK, TP
86  2019 [Verification of Pharmacokinetic Approaches in Prior Drug Development]. PD, PK
87  2018 A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. RP2D
88  2018 A meta-learning framework using representation learning to predict drug-drug interaction. PU
89  2018 A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System. AEs, AI, AR, CR, MI, SRSs
90  2018 A novel integrated action crossing method for drug-drug interaction prediction in non-communicable diseases. IAC, NCDs, PK
91  2018 A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide. AUC, PBPK
92  2018 A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis. LHRH-R, OATP1B3, OCT2, PBPK
93  2018 A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4. PBPK
94  2018 A Pooled Analysis of Pharmacokinetic Variability Information for Common Probe Substrates Used in Drug-Drug Interaction Studies. PK
95  2018 Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method. fm, PBPK
96  2018 An update on efflux and uptake transporters as determinants of statin response. ABC, PK, SLC
97  2018 Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ARVs
98  2018 Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. PBPK
99  2018 Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. IVIVE, PBPK
100  2018 Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan. MEM, NMDA, YKS